Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019028689) ODM-201 CRYSTALLINE FORM, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION THEREOF
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/028689 International Application No.: PCT/CN2017/096547
Publication Date: 14.02.2019 International Filing Date: 09.08.2017
IPC:
C07D 231/14 (2006.01) ,A61K 31/4155 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
231
Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
02
not condensed with other rings
10
having two or three double bonds between ring members or between ring members and non-ring members
14
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
415
1,2-Diazoles
4155
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
杭州领业医药科技有限公司 SOLIPHARMA LLC [CN/CN]; 中国浙江省杭州市 杭州经济技术开发区6号大街452号1幢2A06室徐银荣 XU Yinrong Bldg 1 Suite 2A06, 452 6th Ave, Hangzhou Economic and Technology Development Area Hangzhou, Zhejiang 310018, CN
Inventors:
盛晓红 SHENG, Xiaohong; CN
盛晓霞 SHENG, Xiaoxia; CN
Priority Data:
Title (EN) ODM-201 CRYSTALLINE FORM, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION THEREOF
(FR) FORME CRISTALLINE D'ODM-201, SON PROCÉDÉ DE PRÉPARATION ET COMPOSITION PHARMACEUTIQUE CORRESPONDANTE
(ZH) ODM-201晶型及其制备方法和药物组合物
Abstract:
(EN) The present invention relates to a crystalline form of N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)prop-2-yl)-5-(1-hydroxylethyl)-1H-pyrazole-3-carboxamide (namely, ODM-201). The ODM-201 crystalline form of the present invention has one or more improved properties compared to known ODM-201. The present invention further relates to a method for preparing the ODM-201 crystalline form, a pharmaceutical composition thereof, and a use thereof in the preparation of a medicament for the treatment of nuclear receptor, specifically steroid receptor, and more specifically androgen receptor (AR)-dependent diseases and conditions.
(FR) La présente invention concerne une forme cristalline de N-((S)-1-(3-(3-chloro-4-cyanophényl)-1H-pyrazol-1-yl)prop-2-yl)-5-(1-hydroxyléthyl)-1H-pyrazole-3-carboxamide (à savoir ODM-201). La forme cristalline d'ODM-201 selon la présente invention, présente une ou plusieurs propriétés améliorées par rapport à l'ODM-201 connue. La présente invention concerne en outre un procédé de préparation de la forme cristalline d'ODM-201, une composition pharmaceutique de celle-ci, et une utilisation de celle-ci dans la préparation d'un médicament pour le traitement d'un récepteur nucléaire, en particulier d'un récepteur de stéroïdes, et plus particulièrement de maladies et d'états pathologiques dépendant du récepteur des androgènes (AR).
(ZH) 本发明涉及N-((S)-1-(3-(3-氯-4-氰基苯基)-1H-吡唑-1-基)丙-2-基)-5-(1-羟基乙基)-1H-吡唑-3-甲酰胺(即ODM-201)的晶型,与已知的ODM-201相比,本发明的ODM-201晶型具有一种或多种改进的特性。本发明还涉及所述ODM-201晶型的制备方法,其药物组合物及其在制备用于治疗核受体、特别是类固醇受体、尤其是雄激素受体(`AR)依赖型疾病和症状的药物中的用途。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)